Patent · US Active

Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors

US8507502B2 · kind B2 · utility

1Cited by

0References

19Claims

0Family size

Assignee

National Health Research Institutes · TW

Inventors

Hsing-Pang Hsieh · Taipei, TW
Selvaraj Mohane Coumar · Puducherry, IN
Tsu-An Hsu · Harleysville, US
Wen-Hsing Lin · New Taipei, TW
Yi Chen · Taipei, TW
Yu-Sheng Chao · Taipei, TW

Key dates

Filing date	Nov 9, 2009
Grant date	Aug 13, 2013
Priority date	—
Expiry date	Nov 5, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D495/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Fused bicyclic or tricyclic compounds of formula (I):wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.